Methods of treating cancers with CT45 targeted therapies
AssigneesThe University of Chicago, Max-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E. V.
InventorsErnst Lengyel, Matthias Mann, Marion Curtis, Fabian Coscia
Life of this patent
Estimating the term…
Abstract
The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.
Claims6
An in vitro CT45 targeting agent comprising i) isolated dendritic cells comprising an extra-chromosomal CT45 polypeptide;
- or ii) an isolated dendritic cell primed with a CT45 polypeptide;
- wherein the CT45 polypeptide consists of a polypeptide that has the length and amino acid sequence of one of SEQ ID NOS:
- 1-6 or 29-33.
Dependencies are inferred from the claim text.